دورية أكاديمية
أعرض في EDS

Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart.

التفاصيل البيبلوغرافية
العنوان: Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart.
المؤلفون: Korste S; Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany., Settelmeier S; Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany., Michel L; Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany., Odersky A; Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany., Stock P; Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany., Reyes F; Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany., Haj-Yehia E; Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany., Anker MS; Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, 12203 Berlin, Germany.; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.; Berlin Institute of Health Center for Regenerative Therapies (BCRT), 13353 Berlin, Germany.; German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, 10785 Berlin, Germany., Grüneboom A; Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., 44139 Dortmund, Germany., Hendgen-Cotta UB; Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany., Rassaf T; Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany., Totzeck M; Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2023 Mar 23; Vol. 24 (7). Date of Electronic Publication: 2023 Mar 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Anthracyclines*/pharmacology , Anthracyclines*/therapeutic use , Neoplasms*, Animals ; Mice ; Endothelial Cells/metabolism ; Immunotherapy/methods ; Signal Transduction ; B7-H1 Antigen/metabolism
مستخلص: Cancer survival rates have increased significantly because of improvements in therapy regimes and novel immunomodulatory drugs. Recently, combination therapies of anthracyclines and immune checkpoint inhibitors (ICIs) have been proposed to maximize neoplastic cell removal. However, it has been speculated that a priori anthracycline exposure may prone the heart vulnerable to increased toxicity from subsequent ICI therapy, such as an anti-programmed cell death protein 1 (PD1) inhibitor. Here, we used a high-dose anthracycline mouse model to characterize the role of the PD1 immune checkpoint signaling pathway in cardiac tissue using flow cytometry and immunostaining. Anthracycline treatment led to decreased heart function, increased concentration of markers of cell death after six days and a change in heart cell population composition with fewer cardiomyocytes. At the same time point, the number of PD1 ligand (PDL1)-positive immune cells and endothelial cells in the heart decreased significantly. The results suggest that PD1/PDL1 signaling is affected after anthracycline treatment, which may contribute to an increased susceptibility to immune-related adverse events of subsequent anti-PD1/PDL1 cancer therapy.
References: N Engl J Med. 2018 Nov 29;379(22):2108-2121. (PMID: 30345906)
Front Cardiovasc Med. 2020 Mar 18;7:26. (PMID: 32258060)
Lancet. 2020 Dec 5;396(10265):1817-1828. (PMID: 33278935)
Front Immunol. 2018 Jul 30;9:1774. (PMID: 30105035)
EBioMedicine. 2021 Jul;69:103456. (PMID: 34233258)
Biochem Pharmacol. 2021 Mar;185:114410. (PMID: 33428897)
Eur Heart J. 2022 Jan 31;43(4):316-329. (PMID: 34389849)
Cardiooncology. 2019 Apr 25;5:2. (PMID: 32154009)
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. (PMID: 30242316)
Lancet. 2020 Mar 28;395(10229):1078-1088. (PMID: 32222192)
Int J Cardiol Heart Vasc. 2019 Sep 07;25:100420. (PMID: 31517036)
Breast Cancer Res Treat. 2022 May;193(1):21-35. (PMID: 35235095)
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870)
Science. 2018 Mar 23;359(6382):1350-1355. (PMID: 29567705)
N Engl J Med. 2020 Feb 27;382(9):810-821. (PMID: 32101663)
Nat Methods. 2012 Jul;9(7):671-5. (PMID: 22930834)
ACS Appl Mater Interfaces. 2022 Feb 23;14(7):8782-8792. (PMID: 35138103)
J Vis Exp. 2021 Feb 13;(168):. (PMID: 33645572)
Circulation. 2015 Jun 2;131(22):1981-8. (PMID: 25948538)
PLoS One. 2015 Apr 22;10(4):e0124059. (PMID: 25902191)
Theranostics. 2022 Jan 31;12(5):1999-2014. (PMID: 35265195)
Nat Rev Cardiol. 2015 Sep;12(9):547-58. (PMID: 25962976)
Biochem Biophys Res Commun. 2020 Feb 5;522(2):402-407. (PMID: 31767150)
FASEB J. 2019 Oct;33(10):11096-11108. (PMID: 31291545)
J Am Coll Cardiol. 2010 Jan 19;55(3):213-20. (PMID: 20117401)
Phytomedicine. 2022 Mar 2;99:154027. (PMID: 35278898)
Br J Haematol. 2022 Jan;196(1):127-135. (PMID: 34618912)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
Turk J Biol. 2020 Feb 17;44(1):15-23. (PMID: 32123492)
Cell Death Dis. 2021 Apr 1;12(4):339. (PMID: 33795647)
Lancet. 2020 Oct 10;396(10257):1090-1100. (PMID: 32966830)
Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2435-42. (PMID: 27338072)
Cells. 2022 Mar 18;11(6):. (PMID: 35326493)
J Surg Res. 2009 May 15;153(2):326-31. (PMID: 18952236)
Herz. 2020 Nov;45(7):645-651. (PMID: 32533218)
Nature. 2011 Dec 21;480(7378):480-9. (PMID: 22193102)
Biochim Biophys Acta Mol Cell Res. 2020 Mar;1867(3):118493. (PMID: 31233802)
Toxicol Pathol. 2013;41(8):1146-58. (PMID: 23531791)
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1239-E1248. (PMID: 29367423)
Cardiovasc Res. 2023 Jan 18;118(17):3360-3373. (PMID: 35258628)
JAMA Oncol. 2020 Nov 01;6(11):1778-1782. (PMID: 32910151)
Front Pharmacol. 2022 Feb 08;13:811406. (PMID: 35211017)
N Engl J Med. 2001 Mar 15;344(11):783-92. (PMID: 11248153)
Cell Death Differ. 2020 Feb;27(2):540-555. (PMID: 31209361)
Cardiovasc Res. 2021 Jan 1;117(1):43-59. (PMID: 32365197)
معلومات مُعتمدة: FU356/12-1 Deutsche Forschungsgemeinschaft
فهرسة مساهمة: Keywords: cardio-oncology; cardiotoxicity; doxorubicin; immune checkpoint inhibitor; programmed cell death ligand 1
المشرفين على المادة: 0 (Anthracyclines)
0 (B7-H1 Antigen)
تواريخ الأحداث: Date Created: 20230413 Date Completed: 20230414 Latest Revision: 20230415
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10094326
DOI: 10.3390/ijms24076052
PMID: 37047026
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms24076052